Amgen (AMGN – Analyst Report) is a step closer to gaining EU approval for its cholesterol management candidate, Repatha (evolocumab) with the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of the experimental treatment in certain patients with high cholesterol. Read More
California Assembly Passes Bill to Nullify in Practice Some FDA Restrictions on Terminal Patients
SACRAMENTO, Ca. (May 24, 2015) – On Tuesday, the California state Assembly passed a bill that would effectively nullify in practice certain Food and Drug Administration (FDA) rules that prevent terminally ill patients from accessing experimental treatments. The vote was 74-2.
Introduced in January by Asm. Ian Calderon (D-Whittier) and nine bipartisan co-sponsors, Assembly Bill 164 (AB159) gives terminally ill patients access to medicines that have not been given final approval for use by the FDA. It passed in the state Assembly on May 18 by a 74-2 vote. Read More
Merck (MRK) To Set Strong Foothold In Cancer Immunotherapy Market With Keytruda
Pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) announced Friday that its drug Keytruda has grabbed a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), for treating patients suffering from advanced melanoma. Read More